Physician profile
Rusty Bergman
NPI 1649277500
$873.60
in general payments reported to CMS, 2019-2025
16 companies · $711 in 2025
The $711 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $163 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $178.31 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $163.49 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $87.45 | 2025 | Rexulti |
| Lilly USA, LLC | $73.33 | 2025 | Kisunla, Jardiance |
| Cequr Corporation | $53.00 | 2024-2025 | Cequr Simplicity |
| Novo Nordisk INC | $50.82 | 2025 | Ozempic, Rybelsus |
| Amgen INC. | $48.16 | 2024-2025 | Prolia, Evenity, Repatha |
| Teva Pharmaceuticals USA, INC. | $45.39 | 2024-2025 | Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $39.78 | 2024-2025 | Fanapt, Hetlioz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.97 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $27.35 | 2024-2025 | Arexvy, Shingrix, Bexsero |
| Pfizer INC. | $17.84 | 2025 | |
| Gilead Sciences, INC. | $17.53 | 2025 | |
| Eisai INC. | $15.38 | 2025 | |
| Azurity Pharmaceuticals, INC. | $14.76 | 2025 | Alvesco |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $13.04 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rusty Bergman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.